Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
EARLY_PHASE1
4
about 3.3 years
18+
1 site in OH
About this study
This trial is testing whether a new imaging agent called 18F-Clofarabine (CFA) can be used to image cancer metabolism. The goal is to see if CFA can measure deoxycytidine kinase activity, which helps determine how well certain cancer drugs are taken up by cancer cells.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take 18F-Clofarabine
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
injection (Injection)
Primary: Evaluate CFA as a PET imaging agent
Secondary: Adverse Events, Correlate CFA uptake with OS, Correlate CFA uptake with PFS, Correlate CFA uptake with conventional imaging
Oncology